|Bid||11.76 x 800|
|Ask||11.77 x 800|
|Day's Range||11.64 - 12.50|
|52 Week Range||10.37 - 30.85|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking at a stock holistically. Today I've chosen t...
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance's Botox-like therapy could be used for a broad number of therapeutic as well as aesthetic uses, its leaders say. Regulators will have the final say.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Anyone researching Revance Therapeutics, Inc. (NASDAQ:RVNC) might want to consider the historical volatility of the share pri...
Revance Therapeutics Inc is a clinical-stage biopharmaceutical company. Revance Therapeutics Inc had annual average EBITDA growth of 21.60% over the past five years. Warning! GuruFocus has detected 5 Warning Signs with RVNC.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
If you want to know who really controls Revance Therapeutics, Inc. (NASDAQ:RVNC), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year. More than 95 percent of patients administered with Revance's long-acting neuromodulator injection RT002 were found to have none or mild frown lines after four weeks, according to data from the third late-stage study. The treatment, which requires two or less doses a year, was effective in maintaining reduced wrinkle severity in patients for a median duration of 24 weeks.
Dan Browne has been the CEO of Revance Therapeutics Inc (NASDAQ:RVNC) since 2002. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
If you’re interested in Revance Therapeutics Inc (NASDAQ:RVNC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...
Jim Cramer and technician Tim Collins review Allergan's stock charts to figure out what might be next for the Botox maker.